Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).

doi:10.1007/s10549-015-3435-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).

Breast cancer research and treatment - 1 Jun 2015

Kaklamani Virginia G, Jeruss Jacqueline S, Hughes Elisha, Siziopikou Kalliopi, Timms Kirsten M, Gutin Alexander, Abkevich Victor, Sangale Zaina, Solimeno Cara, Brown Krystal L, Jones Joshua, Hartman Anne-Renee, Meservey Caitlin, Jovanovic Borko, Helenowski Irene, Khan Seema A, Bethke Kevin, Hansen Nora, Uthe Regina, Giordano Sara, Rosen Steven, Hoskins Kent, Von Roenn Jamie, Jain Sarika, Parini Vamsi, Gradishar William

Abstract excerpt

The purpose of this study is to evaluate the efficacy and safety of neoadjuvant treatment with carboplatin and eribulin in patients with early-stage triple negative breast cancer (TNBC), and to explore biomarkers based on DNA and protein expression profiles as predictors of response. Patients with histologically confirmed early-stage TNBC received carboplatin AUC 6 iv every 21 days, and eribulin 1.4 mg/m(2) day 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Ketones

Share to Neoadjuvant Therapy

Share to Neoplasm Grading

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed

Identifiers

PMID: 26006067
DOI: 10.1007/s10549-015-3435-y

Genes

CDK2
CDK4
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).PMID 26006067Read ↗

Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.Semantic proximity Read ↗

The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancerSemantic proximity Read ↗

Biomarker Guided Chemotherapy and Immunotherapy Response in Asian Triple-Negative Breast Cancer: A Systematic ReviewSemantic proximity Read ↗

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trialSemantic proximity Read ↗

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.Semantic proximity Read ↗

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.Semantic proximity Read ↗

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerSemantic proximity Read ↗

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read ↗

Targeted and cytotoxic inhibitors used in the treatment of breast cancerSemantic proximity Read ↗

Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.Semantic proximity Read ↗

Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer.Semantic proximity Read ↗

Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.